Valneva's Audited 2025 Results and 2026 Outlook Set for Release

Valneva releases full 2025 results, showing revenue growth but lower cash. 2026 guidance set as key Phase 3 Lyme vaccine data nears.

Investor attention turns to Valneva this Wednesday, March 18, as the biotech company prepares to publish its complete, audited financial statements for the 2025 fiscal year. While preliminary figures released in February provided a broad outline, the final report will deliver a comprehensive view, including detailed cash flow information and the structure of the company's debt.

Financial Performance and Forward Guidance

The company reported total revenues of €174.7 million for 2025, marking a slight increase over the prior year. This growth was driven by its core proprietary products, even as third-party manufacturing sales experienced a decline. A key focus will be on liquidity: Valneva's cash and cash equivalents decreased from €168.3 million to €109.7 million. This reduction reflects ongoing investments in research and development but was mitigated by a completed debt refinancing initiative.

Looking ahead, management has provided revenue guidance for 2026, projecting a range of €155 million to €170 million. The anticipated dip from 2025 levels is attributed to the planned phase-out of certain third-party revenue streams—a development already factored into market expectations for some time.

Clinical Catalysts on the Horizon

Beyond the financials, the market is closely monitoring two significant clinical milestones expected in the coming year. These pipeline events are poised to shape Valneva's long-term trajectory:

• VLA15 (Lyme Disease Vaccine): Top-line Phase 3 trial data are anticipated in the first half of 2026. Positive results would trigger regulatory submission plans by development partner Pfizer. Success here could grant Valneva its fourth proprietary marketed vaccine, further diversifying its business beyond its travel vaccine portfolio.
• S4V2 (Tetravalent Shigella Vaccine): Initial Phase 2 clinical data are expected, with a development decision scheduled for the second half of the year.

The VLA15 program, in particular, is viewed as a major potential catalyst for the stock.

Market Context and Strategic Focus

Ahead of the Wednesday webcast, Valneva shares trade approximately 11% below their 52-week high of €5.16, though they remain positioned above all key moving averages. Analysts will be listening for management to detail its specific liquidity strategy for 2026 and to clarify which operational milestones are tied to future capital allocation.

The upcoming report will offer investors a clearer picture of how the company is navigating its transition, balancing near-term financial management with the costly but critical advancement of its late-stage clinical assets.